Clinical Trial Search

Primary: Part 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and SHP-674-Related TEAEs During the Tolerability Assessment Period — 3; 3 Participants

Primary: Effect of LJPC-401 Versus Placebo on Blood Iron Levels — -32.8; -2.5 Percent Change — p=< 0.0001

Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants

Primary: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score — -48.33; -49.72; -61.07; -57.35 percentage of score change — p=< 0.001

Primary: Duration of Severe (Grade 4) Neutropenia in Cycle 1 — 8; 1; 2; 14 days — p=<0.0001

Primary: Respiratory Syncytial Virus (RSV) Viral Load-time Curve From Immediately Prior to First Dose of JNJ-53718678 Through Day 5 (AUC [Day 1-5]) — 26.13; 25.10 log10…

Primary: Feasibility and Safety of Ticagrelor in Hemodialysis Patients — 1; 3 Participants — p=0.32

Primary: Objective Tumor Response After One Course of Therapy — 5; 5; 11 Participants

Primary: Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR) — 45.7; 0.0; 0.0; 0.0…

Primary: Percentage of Menstrual Cycle Responders — 7.7; 0; 0; 0 percentage of participants — p=0.300

Primary: Mean Change in Schirmer's Test Score From Baseline to 84 Days — 10.8; 11.0; 6.0 mm

Primary: RVIP Target Hit and False Alarm (Number of Responses) — 23.4; 22.8; 19.7; 14.88 Number of responses — p=0.898

Primary: Radiographic Objective Response Rate (ORR) - Part 2 Cohort — 3.3 Percent of participants

Primary: Phase 1: Recommended Phase 2 Dose (RP2D) — 75 mcg/m^2

Primary: Percentage of Participants With an Objective Response (Partial Response (PR) + Complete Response (CR) for Sunitinib in Participants With Relapsed or Refractory Thymoma…